U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07057778) titled 'Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP' on June 30.
Brief Summary: Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia (ITP)
Intervention:
DRUG: Iguratimod
oral iguratimod at 25mg twice daily for 26 weeks
DRUG: low-dose rituximab
rituximab 100mg once weekly for 6 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Peking University People's Hospi...